Boron neutron capture therapy (BNCT) is of increasing interest for the treatment of cancers such as gliomas and melanomas.
He nuclei with high kinetic energy (2.4 MeV). The a-particle and lithium ion dissipate their kinetic energy before traveling one cell diameter (ca.10 mm) in biological tissue and damage is limited to the cell containing the boron. One of the major challenges in the development of BNCT has been the design and synthesis of boron compounds 2) which have the capacity for selectively targeting malignant cells and which can be accumulated intracellularly at a sufficient concentration to deliver an effective radiation dosage. One stable, nontoxic, and synthetically amenable functionality that allows significant amounts of boron incorporation for BNCT is the 1,2-dicarba-closo-dodecaborane (o-carborane) cage. Carborane-containing nucleic acid precursors, 3) amino acids, 4) porphyrins 5) and DNA binders 6) have been synthesized in attempts to target boron to tumors. From the viewpoint of potential for the rapid targeting of tumor cells, nuclear receptor ligands which bind to estrogen, thyroid, progesterone and retinoic acid receptors are promising synthetic targets, although it is not clear whether a concentration sufficient to deliver an effective dosage can be achieved. Several estrogenrelated compounds bearing carboranes have been reported. 7) In contrast to the interest in carboranes for BNCT, little attention has been paid to carboranes as building blocks of biologically active compounds. Most carborane-containing compounds which have been synthesized are composed of cellular building blocks (nucleic acid, amino acid, etc.), to which carborane units are added. Carboranes are a class of carboncontaining polyhedral boron-cluster compounds. 8) One of their most striking features is the ability of the 2 carbon atoms and 10 boron atoms to adopt icosahedral geometry in which the carbon and boron atoms are hexacoordinated. This feature of the icosahedral structure gives rise to the unusual properties of such molecules and their carbon and boron derivatives. For example, the stability of the carborane cage has been demonstrated under many reaction conditions and the hydrophobic character is comparable to that of hydrocarbons. In this article, we describe the synthesis and biological evaluation of carborane-containing retinoids in order to test the applicability of carboranes as a hydrophobic moiety. Figure 1 illustrates the structure of 1,2-dicarba-closo-dodecaborane (carborane). In icosahedral cage structures throughout this paper, closed circles ( • ) represent carbon atom and other vertices represent BH units.
Design and Synthesis of Carborane-Containing Retinoids Retinoids, i.e., all-trans-retinoic acid (Fig. 2, 1 ) and its analogs, are of particular interest as chemopreventive and therapeutic agents in the fields of dermatology and oncology. 9) Retinoids are able to induce differentiation of a wide spectrum of cell types, such as embryonal carcinoma cells, promyelocytic leukemia cells, and normal and malignant keratinocytes.
10) The mechanism of these effects on cell differentiation and morphogenesis involves modulation of specific gene transcription through the retinoic acid receptors (RAR-a, b, g).
11) A number of retinoids are known to be agonists of retinoic acid, and they bind to RARs. The retinoidal actions are also modulated by retinoid X receptors (RXR-a, b, g), which bind 9-cis-retinoic acid (2) . 10) Recent work on the design of synthetic retinoids 12) and the availability of three-dimensional (3D) structure information 13) have revealed the structural requirements for the appearance of retinoidal activity, including subtype-selectivity. For example, the retinobenzoic acids Am80 (3) and Am555S (4), which activate RAR-a and -b, exhibit potent retinoidal activities. High binding affinity for RAR requires a carboxylic acid moiety and an appropriate hydrophobic group located at a suitable position on the molecule, such as in 3 and 4.
12) A retinobenzoic acid with a bulky hydrophobic group, CD-394 (5), has been reported to be a strong differentiation inducer of F9 mouse embryonal carcinoma cells. 14) However, the differentiation activity of 5 toward human promyelocytic leukemia cells (HL-60) is only moderate and the maximum response obtained with 5 was smaller than that with 3. It appears that 5 may be a partial agonist-antagonist. Introduction of a bulkier hydrophobic group, such as the pentacyclotetradecane (diamantyl) group (TD550, 6), afforded clear antagonistic activity. 15) These results led us to synthesize and investigate compounds having carboranes as a hydrophobic moiety, as shown in Fig. 3 .
The syntheses of the designed molecules are summarized in Chart 1. Compounds 7 and 8 were prepared from 1-phenyl-1,2-dicarba-closo-dodecaborane (13a), which is easily prepared from ethynylbenzene and decaborane(14) (B 10 H 14 ). 16) Compound 13a was converted to 1-phenyl-2-alkyl-1,2-dicarba-closo-dodecaboranes (13b-d) by lithiation followed by reaction with alkyl halide, in high yields. Nitration of 13a with a mixed acid system has been reported to afford a mixture of 3-and 4-nitro isomers, 16) or a mixture of 2-and 4-nitro isomers 17) under similar conditions. We found that nitration of 13a with mixed acid/CH 2 Cl 2 afforded the 4-nitro (14a) and 3-nitro (15a) isomers in 65% and 19% yields, respectively. The 3-nitro isomers were the major isomers in the case of nitration of 1-phenyl-2-alkyl-1,2-carboranes (13b-d). 18) Isolated yields of the 4-nitro (14b-d) and 3-nitro (15b-d) isomers were 35-37% and 47-57% . Catalytic hydrogenation of the nitro group of 14 or 15 followed by reaction with terephthalic acid monomethyl ester chloride gave esters in yields of 58-97%. Hydrolysis of the ester group gave 7 and 8 in yields of 71-98%. Compound 9 was prepared from 2-iodoanisole. Palladium-catalyzed coupling of 2-iodoanisole with ethynyltrimethylsilane followed by deprotection of the trimethylsilyl group gave 2-ethynylanisole (16) (89%). Reaction of 16 with decaborane (14) in the presence of acetonitrile afforded 1-(2Ј-methoxyphenyl)-1,2-dicarbacloso-dodecaborane (17) (49%). Nitration of 17 gave the 5Ј-nitro isomer as the sole product in 70% yield. Catalytic hydrogenation, followed by coupling with terephthalic acid monomethyl ester chloride and hydrolysis afforded 9 (68%). Compound 10, in which the distance between the hydrophobic carborane group and the carboxylic acid moiety is shortened, was prepared from 3-trimethylsilyl-2-propyn-1-al (19) . Reaction of 19 with triethylphosphonoacetate in the presence of sodium hydride gave 20 (65%). Deprotection of the trimethylsilyl group gave ethyl pent-2-en-4-ynoic acid (21) (79%). Decaboranylation with decaborane(14) gave the unsaturated ester 22 (64%), which was converted to the acyl chloride by alkaline hydrolysis and treatment with oxalyl chloride. Condensation of the acyl chloride with methyl 4-aminobenzoate followed by hydrolysis gave 10 (13%). Compounds 11 and 12 were prepared from ethyl 4-(25) and 3-ethynylbenzoate (26), respectively. The ethynyl benzoates were obtained from ethyl 4-and 3-bromobenzoates using the reported method. 19) The ethyl ethynylbenzoates 25 and 26 were converted to acyl chlorides by alkaline hydrolysis and treatment with oxalyl chloride. Condensation of the acyl chlorides with methyl 4-aminobenzoate followed by hydrolysis gave 11 and 12 (20-37%) .
Biological Activity of Carborane-Containing Retinoids The biological activity of compounds 7-12 was examined by use of the assay of differentiation induction of HL-60 cells to granulocytes. 20) The morphological changes were examined by microscopy after Wright-Giemsa staining, and the percentages of differentiated cells were determined with nitro blue tetrazolium (NBT) reduction assay as a functional marker of differentiation.
Compounds bearing 1,2-carborane at the 4-position of the benzene nucleus (7, 11) were completely inactive as differentiation inducers at concentrations below 10 Ϫ6 M. However, examination of their ability to inhibit the differentiation-inducing ability of Am80 (3) indicated that these carborane-containing compounds are retinoidal antagonists (Fig. 4) ; they inhibited the activity of Am80 at the concentration of 1ϫ10 Ϫ6 M. For example, the response to Am80 at 3.3ϫ 10 Ϫ10 M (55% NBT positive cells) was reduced in the presence of 1ϫ10 Ϫ6 M 7a to 23%. The compounds bearing an alkyl group at the 2-position of the 1,2-carborane cage (7b- Ϫ8 , 1ϫ10 Ϫ7 , 3.3ϫ10 Ϫ7 and 1ϫ10 Ϫ6 M 7b, afforded 62, 53, 43, 15 and 6% differentiated cells, respectively, in a separate experiment (Fig. 5) ). Compound 11, in which the -NHCO-group of 7a is replaced with -CONHand compound 9, which is the 1,2-carborane analog of CD-394 (5) or TD550 (6), exhibited a similar antagonistic activity to that of 7a.
On the other hand, the biological activities of the compounds with 1,2-carborane at the 3-position of the benzene nucleus (8, 12) were different in nature from that of the 4- The percentage of differentiation were averages of four repetition for each experiment. Each point represents the meanϮS.E. (nϭ4). carboranyl derivatives 7 and 11. Compounds 8 and 12 were almost inactive as differentiation inducers at concentrations below 10 Ϫ6 M (less than 10% cellular response). However, the extent of differentiation (less than 10%) induced by 1ϫ 10 Ϫ6 M 8 or 12 was significantly increased by the addition of 1ϫ10 Ϫ7 M HX630, (Fig. 2, 29 ) which is a potent retinoidal synergist 21) (Fig. 6 ). For example, the response to 8c at 1ϫ 10 Ϫ6 M (less than 10%) was enhanced to 93% in the presence of 1ϫ10 Ϫ7 M HX630. The synergistic activities of HX630 result from binding to the RXR site of RXR-RAR heterodimers, and the binding enhances the activities of RARspecific ligands such as Am80. The smaller molecule 10 exhibited a similar activity to that of 8 and 12. These compounds show no antagonistic activity (such as those of 7, 9 and 11) at 1ϫ10
The carborane-containing compounds show clear substituent effects, as follows. 1) The 4-carboranyl-substituted compounds showed antagonistic activity but no agonistic activity even in the presence of the potent synergist HX630. 2) The 3-carboranyl-substituted compounds showed potential agonistic activity, but no antagonistic activity. Compound 9, which was designed as a 1,2-carborane analog of the retinoid partial agonist CD-394 (5) or antagonist TD550 (6), expectedly exhibited antagonistic activity almost equal to that of TD550 (6) and weak agonistic activity. These results indicate that the carborane cage has similar effects to the diamantyl group. The substituent effects of carboranes also suggest that the presence of methoxy groups in which the methyl group is directed to the outer side by a bulky substituent in 9 and 6 is important for the appearance of the characteristic activities.
The results of this study demonstrate that carboranes are applicable as the hydrophobic moiety of biologically active molecules. In addition, there is a possibility that the carborane-containing retinoids synthesized here for the first time may be of value for BNCT of cancers with retinoid receptors. Receptor site density is generally believed to be too low to afford a ligand concentration sufficient to deliver an effective radiation dose in BNCT, however, the compounds with mild affinity for RAR and non-toxicity for cells will be possibly effective by concentrating boron in the cell nucleus.
Experimental
General Remarks Melting points were obtained on a Yanagimoto micro hot stage without correction. 1-Phenyl-1,2-dicarba-closo-dodecaborane (13a) A mixture of ethynylbenzene (5.51 g, 53.9 mmol) and decaborane(14) (2.64 g, 21.6 mmol) in acetonitrile (5.5 ml) and benzene (55 ml) was refluxed for 4 d under an Ar atmosphere, then concentrated. Purification by silica gel column chromatography (eluent: hexane) gave 13a (74% 1-Isobutyl-2-phenyl-1,2-dicarba-closo-dodecaborane (13d) 13d was prepared from 13a (1.00 g, 4.54 mmol), n-BuLi (1.6 M solution in hexane 2.55 ml, 4.08 mmol) and isobutyl iodide (708 mg, 4.54 mmol) in a manner similar to that used for the preparation of 13b. Purification by silica gel column chromatography (eluent: hexane) gave 13d (50%) and recovered 13a (39%). General Procedure for Nitration of 13a-d: 4-(2-Methyl-1,2-dicarbacloso-dodecaboran-1-yl)nitrobenzene (14b) and 3-(2-Methyl-1,2-dicarba-closo-dodecaboran-1-yl)nitrobenzene (15b) A solution of 13b (900 mg, 3.84 mmol) in CH 2 Cl 2 (17.5 ml) was added dropwise to a solution of concentrated HNO 3 and concentrated H 2 SO 4 (15 : 85, v/v) (17.5 ml) at 0°C. The mixture was stirred at room temperature for 4 h, then poured onto ice and extracted with CH 2 Cl 2 . The organic layer was washed with brine, dried over Na 2 SO 4 , and concentrated. Purification by silica gel flash column chromatography (eluent: hexane/AcOEt, 30 : 1) gave 14b (34%) and 15b (57% Methyl-1,2-dicarba-closo-dodecaboran-1-yl) phenylcarbamoyl]benzoic Acid (7b) A solution of 14b (349 mg, 1.25 mmol) in EtOH (25 ml) was hydrogenated over 10% Pd/C (87 mg) at room temperature for 1 h under atmospheric pressure of hydrogen. After removal of the catalyst by filtration, the filtrate was concentrated to give 4-(2-methyl-1,2-dicarba-closo-dodecaboran-1-yl)aniline (95% 6 Hz) . To a solution of the amine (100 mg, 0.401 mmol) in pyridine (2.5 ml) was added terephthalic acid monomethyl ester chloride (119 mg, 0.599 mmol) at 0°C. The mixture was stirred at room temperature for 3 h. The reaction was quenched with 2 N HCl and the whole was extracted with AcOEt. The organic layer was washed with water, saturated aqueous NaHCO 3 , water and brine, dried over Na 2 6 Hz) . To a solution of the methyl benzoate (140 mg, 0.34 mmol) in THF (2 ml) was added 1 N KOH (0.68 ml), and the mixture was stirred at room temperature for 14 h. The reaction was quenched with 2 N HCl, and the whole was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 2H, d, Jϭ8.6 Hz), 8.25 (1H, br s), 10.61 (1H, s), 13.30 (1H, br) 
1-(2-Methoxyphenyl)-1,2,-dicarba-closo-dodecaborane (17)
A mixture of 16 (1.30 g, 9.84 mmol) and decaborane (14) (1.80 g, 14.7 mmol) in acetonitrile (5 ml) and benzene (50 ml) was refluxed for 23 h under an Ar atmosphere, then concentrated. Purification by silica gel flash column chromatography (eluent: hexane to hexane/AcOEt, 40 : 1) gave 17 (49%). 
Ethyl 5-Trimethylsilyl-(E )-2-penten-4-ynoate (20)
To a suspension of NaH (556 mg, 13.9 mmol) in THF (7 ml) was added dropwise ethyl diethylphosphonoacetate (3.12 g, 13.9 mmol) in THF (7 ml) under an Ar at-mosphere. The mixture was stirred at room temperature for 30 min, then 19 in THF (7 ml) was added dropwise at 0°C. After having been stirred for 1.5 h at room temperature, the reaction mixture was poured into ice water, and extracted with AcOEt. The organic layer was washed with brine, dried over Na 2 SO 4 , then concentrated. The residue was purified by silica gel flash column chromatography (eluent: hexane to hexane/AcOEt, 50 : 1) to give 20 (65% Ethyl (E )-2-Penten-4-ynoate (21) K 2 CO 3 (563 mg, 4.07 mmol) was added to a solution of 20 (800 mg, 4.07 mmol) in EtOH (10 ml), and the mixture was stirred at room temperature for 1 h. The reaction was quenched with 2 N HCl, and extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 13 .00 (1H, br). To a solution of the acid (60 mg, 0.28 mmol) in CH 2 Cl 2 (1 ml) was added oxalyl chloride (53.3 mg, 0.42 mmol) and a catalytic amount of DMF (1 drop). The mixture was stirred for 1 h at room temperature, then concentrated. The residue was dissolved in pyridine (1 ml) and methyl 4-aminobenzoate (46.6 mg, 0.308 mmol) was added. The mixture was stirred for 18 h at room temperature, then the reaction was quenched with 2 N HCl, and the whole was extracted with AcOEt. The organic layer was washed with water, saturated aqueous NaHCO 3 , water and brine, dried over Na 2 SO 4 , and concentrated. Purification by silica gel flash column chromatography (eluent: hexane/AcOEt, 5 : 4-{[4-(1,2-Dicarba-closo-dodecaboran-1-yl)phenyl]carboxamido}ben-zoic Acid (11) To a solution of 27 (374 mg, 1.28 mmol) in THF (5 ml) was added 1 N KOH (3.84 ml), and the mixture was stirred at room temperature for 15 h. The reaction was quenched with 2 N HCl, and the whole was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 , and concentrated. The residual crystals were washed with hexane to give 4-(1,2-dicarba-closo-dodecaboran-1-yl)benzoic acid. 13 .29 (1H, br). To a suspension of the acid (140 mg, 0.53 mmol) in CH 2 Cl 2 (1.5 ml) was added oxalyl chloride (202 mg, 1.59 mmol) and a catalytic amount of DMF (1 drop). The mixture was stirred for 1 h at room temperature, then concentrated. The residue was dissolved in pyridine (1.5 ml) and methyl 4-aminobenzoate (84.0 mg, 0.556 mmol) was added. The mixture was stirred for 15 h at room temperature, then the reaction was quenched with 2 N HCl, and the whole was extracted with AcOEt. The organic layer was washed with water, saturated aqueous NaHCO 3 , water and brine, dried over Na 2 SO 4 , and concentrated. Purification by silica gel flash column chromatography (eluent: hexane/AcOEt, 3 : 1) gave methyl 4-{[4-(1,2-dicarba-closo-dodecaboran-1-yl)phenyl]carboxamido}benzoate (48% from 27). 8 Hz) . To a solution of the methyl benzoate (94 mg, 0.236 mmol) in THF (3 ml) was added 1 N KOH (1.18 ml), and the mixture was stirred at 40°C for 16 h. The reaction was quenched with 2 N HCl, and the whole was extracted with AcOEt. The organic layer was washed with water and brine, dried over Na 2 SO 4 , then concentrated. Purification by silica gel flash column chromatography (eluent: CHCl 3 /MeOH, 5 : 1) gave 11 (41%). 11: Colorless needles (AcOEt); mp Ͼ300°C; 5 Hz) .
Ethyl 3-(1,2-Dicarba-closo-dodecaboran-1-yl)benzoate (28) Compound 28 was prepared from 26 (635 mg, 3.65 mmol) and decaborane (14) (446 mg, 3.65 mmol) in a manner similar to that described for 27. Purifica-
